These ILC1s accumulated within the tumor tissue, where their enrichment was correlated with the heightened expression of inhibitory receptors, such as PD-1, CD200R, NKG2A and B and T lymphocyte attenuator (BTLA), and reduced overall and disease-free survival (Table 3) [53]. The gene discussed is KLRC1; the disease is neoplasm.